Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 4/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.37 |
| ▸ | RIPK3 | Q9Y572 | 3/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6158999 | 0.75 | P2RX7 (0.47) | ALDH1A1GRM2LMNAMAPTSLC6A2 | |
| SCHEMBL6161488 | 0.73 | TGFBR1 (0.40) | MAP3K14MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6159020 | 0.67 | ALDH1A1 (0.39) | GSK3BALDH1A1MAPTSLC6A2SLC6A4 | |
| SCHEMBL4915990 | 0.65 | MAPK14 (0.68) | MAPK14GSK3BMAPK13MAPK12MAPK11 | |
| SCHEMBL6159878 | 0.65 | SLC6A2 (0.40) | GSK3BALDH1A1MAPTSLC6A2SLC6A4 | |
| SCHEMBL5215378 | 0.62 | MAPK14 (0.39) | MAP3K14MAPK14RIPK3GSK3BMAPK13 | |
| SCHEMBL5142281 | 0.62 | PTGS2 (0.52) | PTGS1PTGS2 | |
| SCHEMBL5215409 | 0.62 | MAP3K14 (0.39) | MAP3K14MAPK14RIPK3MAPK13MAPK12 | |
| SCHEMBL27413946 | 0.60 | KDM1A (0.55) | GSK3BALDH1A1LMNA | |
| SCHEMBL5216102 | 0.58 | MAPK14 (0.61) | MAP3K14MAPK14GSK3BMAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967254-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2005-11-22 | — | — | US | claimed |
| EP-1542680-A1 | 1, 4, 5-SUBSTITUTED 1, 2-DIHYDRO-PYRAZOL-3-ONE AND 3-ALKOXY-1H-PYRAZOLE DERIVATIVES S TNF-ALPHA AND INTERLEUKIN LOWERING AGENTS FOR THE TREATMENT OF INFLAMMATIONS | Amgen Inc. (US) | 2005-06-22 | — | — | EP | claimed |
| US-20040058918-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2004-03-25 | — | — | US | claimed |
| WO-2004022055-A1 | 1, 4, 5-SUBSTITUTED 1, 2-DIHYDRO-PYRAZOL-3-ONE AND 3-ALKOXY-1H-PYRAZOLE DERIVATIVES S TNF-ALPHA AND INTERLEUKIN LOWERING AGENTS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC. (US) | 2004-03-18 | — | — | WO | claimed |
| US-6967254-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2005-11-22 | — | — | US | disclosed |
| EP-1542680-A1 | 1, 4, 5-SUBSTITUTED 1, 2-DIHYDRO-PYRAZOL-3-ONE AND 3-ALKOXY-1H-PYRAZOLE DERIVATIVES S TNF-ALPHA AND INTERLEUKIN LOWERING AGENTS FOR THE TREATMENT OF INFLAMMATIONS | Amgen Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040058918-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2004-03-25 | — | — | US | disclosed |
| WO-2004022055-A1 | 1, 4, 5-SUBSTITUTED 1, 2-DIHYDRO-PYRAZOL-3-ONE AND 3-ALKOXY-1H-PYRAZOLE DERIVATIVES S TNF-ALPHA AND INTERLEUKIN LOWERING AGENTS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC. (US) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058918-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MAPT, HMGB1 | MAP3K14 892/4885MAPK14 1197/4885RIPK3 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.